Clinical Trial Update: Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin [Phase 1]

View source ↗

Summary

Phase 1 intratumoral study of SL-172154 in cutaneous squamous cell carcinoma and squamous cell carcinoma of the head and neck was terminated; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• SL-172154 (SIRPα-Fc-CD40L)

Snippet

Sponsor: Shattuck Labs, Inc. | Conditions: Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Status: TERMINATED | Results posted: 2025-02-24